Omnicell, Inc. Q2 2010 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2010. Omnicell, Inc. is a leading provider of medication control and patient safety solutions for acute care health facilities, primarily in the United States. The company operates in a single reportable segment focused on medication and supply dispensing systems. As of August 3, 2010, there were 32,687,549 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q2 2010 | Q2 2009 | YTD 2010 | YTD 2009 |
|---|---|---|---|---|
| Total Revenues | $54,693 | $52,643 | $108,853 | $104,847 |
| Gross Profit | $28,868 | $26,929 | $56,454 | $50,749 |
| Gross Margin | 52.8% | 51.2% | 51.8% | 48.4% |
| Operating Income | $3,492 | $1,317 | $5,001 | $(1,654) |
| Net Income | $1,965 | $904 | $2,944 | $(967) |
| Diluted EPS | $0.06 | $0.03 | $0.09 | $(0.03) |
| Cash & Equivalents (End of Period) | $185,156 | |||
| Operating Cash Flow (YTD) | $12,136 | $5,963 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 3.9% year-over-year for the quarter and 3.8% year-over-year for the six-month period. Product revenue remained flat (0.1% increase Q2, 0.0% YTD), while service revenue grew significantly (18.9% Q2, 19.3% YTD).
- Profitability Improvement: The company returned to profitability, reporting net income of $1.965 million for Q2 2010 compared to $0.904 million in Q2 2009. For the six months ended June 30, 2010, the company reported a net income of $2.944 million, a turnaround from a net loss of $0.967 million in the same period in 2009.
- Margin Expansion: Gross margins improved across both product and service lines. Service gross profit increased 42.1% in Q2 2010 compared to Q2 2009.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased 2.9% in Q2 2010 compared to the prior year, driven by reduced legal fees related to settled litigation and favorable timing effects on accrued vacation.
- Cash Flow: Operating cash flow more than doubled year-over-year for the six-month period ($12.1 million vs. $6.0 million), attributed to improved accounts receivable collections and positive net income.
Outlook, Risks, and Unusual Items
- Subsequent Restructuring: On July 6, 2010, the company approved a plan to close offices in Bangalore, India, and The Woodlands, Texas. The company expects to incur pre-tax restructuring charges of approximately $1.5 million in the quarter ending September 30, 2010.
- Legal Proceedings: The company is defending patent infringement lawsuits filed by Flo Healthcare Solutions, LLC (related to the Rioux Vision acquisition) and Medacist Solutions Group LLC. While the company believes its accruals are adequate, unfavorable outcomes could materially affect financial results.
- Accounting Changes: The company is evaluating the impact of new FASB Accounting Standards Updates (ASU 2009-13 and 2009-14) regarding revenue recognition, which are effective for fiscal years beginning after June 15, 2010. Adoption is planned for fiscal year 2011.
- Stock Repurchase Program: No shares were repurchased during the six months ended June 30, 2010. As of that date, $25.0 million remained authorized for repurchases under the existing program.
- Risk Factors: Key risks include dependence on a limited number of suppliers, potential delays in customer installations affecting revenue recognition, and the impact of healthcare reform legislation on customer spending.
Investor Verification Checklist
- Installation Backlog: Verify the timing of pending installations, as revenue recognition is dependent on installation completion, which can be delayed by customer schedules.
- Service Revenue Sustainability: Assess whether the significant growth in service revenue (driven by purchase orders recognized from prior installation dates) is sustainable or if it reflects a one-time timing effect.
- Legal Contingencies: Monitor the status of the Flo Healthcare and Medacist lawsuits and the adequacy of the $5.25 million pre-acquisition contingency accrual.
- Restructuring Impact: Confirm the timing and magnitude of the $1.5 million restructuring charge expected in Q3 2010 related to the closure of international and domestic offices.
- Supplier Concentration: Review the dependency on the single significant supplier, which accounted for approximately $8.9 million of purchases in the first six months of 2010.